Obesity Doctor: What’s Coming After Ozempic? Inside the New Drug Survodutide
A five-minute overview from an obesity medicine physician of survodutide, a weekly GLP-1 and glucagon injection, covering its mechanism, one trial result and its fatty liver angle.
With Dr. Megan (Board-certified physician in internal medicine, lifestyle medicine and obesity medicine)
Key moments
Tap a moment to play the video from there.
- 0:00Who Dr. Megan isDr. Megan introduces herself and her credentials, says she prescribes weight medications, and previews the topic.
- 0:30Weekly GLP-1 plus glucagonShe says survodutide is a weekly injection that acts as both a GLP-1 agonist and a glucagon receptor agonist.
- 1:00Glucagon as gas and brakesShe compares glucagon and insulin to the gas and the brakes of blood sugar regulation, with the liver acting as a local bank for sugar.
- 1:32Liver glycogen and appetiteShe says glucagon lets the liver release glucose from glycogen and blocks its re-uptake. She adds that it seems to suppress appetite and affect fat metabolism and energy use.
- 2:04Lancet trial weight lossShe cites a 46-week Lancet study of over 300 people with average total body weight loss of 14.9%, which she calls very competitive.
- 2:35Adverse events and phase 3She notes that about 91% of subjects had some sort of adverse event and says the phase three synchronized trials are in the works.
- 2:56Fatty liver disease and MASHShe says the drug seems to improve MASH, which she describes as fatty liver, and explains why she considers fatty liver disease dangerous.
- 3:37Two indications and accessShe expects an FDA approval for fatty liver and argues that two indications could help access for people on Medicaid or Medicare.
- 4:38Closing and coaching offerShe says she will leave study information below, awaits phase 3 data, and promotes her weight loss coaching.
What the video says
In this short video, Dr. Megan, who says she is board-certified in internal medicine, lifestyle medicine and obesity medicine and prescribes weight medications, introduces survodutide as one of several weight medications in development. Her captions spell the name in several ways, but the title and context make clear it is the same drug. She describes it as a weekly injection that acts on both the GLP-1 receptor and the glucagon receptor.
Much of the first half is a plain-language explanation of glucagon. Dr. Megan likens glucagon and insulin to the gas and the brakes for blood sugar. According to her, glucagon signals the liver to break down stored glycogen into glucose and release it into the bloodstream, and it stops the liver from taking sugar back up. She adds that it also seems to affect appetite, fat metabolism and probably how the body burns energy.
On results, she cites a Lancet study of over 300 people lasting 46 weeks, in which average total body weight loss was 14.9%. She calls that very competitive against Wegovy, Ozempic, Mounjaro and Zepbound. She also notes that about 91% of people on the drug had some sort of adverse event, and that phase three trials called the synchronized trials are underway. She expects them to show patterns in efficacy and safety in a much larger group.
She then turns to MASH, the newer name for fatty liver disease, which she describes as a leading driver of end-stage liver disease. Dr. Megan says the drug appears to improve measures of fatty liver disease and that she expects it would likely be approved for it. Having two possible indications, she argues, could widen access, particularly for people on Medicaid or Medicare. The video ends with a pitch for her own weight loss coaching, which covers non-medical aspects such as eating and exercise for people already on a GLP-1.
On each compound
Survodutide0:30
Dr. Megan describes it as a weekly injection that is both a GLP-1 agonist and a glucagon receptor agonist. She cites a 46-week Lancet study of over 300 people with 14.9% average total body weight loss and about 91% reporting some adverse event. She says it seems to improve MASH and that phase three trials are in the works.
See how your DNA reads SurvodutideWhat this video doesn’t settle
- The video gives only one headline result from a single 46-week study and does not describe its design, doses or comparison group.
- The 91% adverse event figure is stated without saying which events occurred or how serious they were.
- Dr. Megan's expectation of FDA approval for fatty liver disease is her own prediction, and the video offers no trial data on that outcome beyond saying measures improved.
Questions this video answers
How does survodutide work?
Dr. Megan says it is a weekly injection that activates both the GLP-1 receptor and the glucagon receptor. She explains that glucagon lets the liver release stored sugar and block its re-uptake. She adds that it also seems to suppress appetite and affect fat metabolism and energy use.
How much weight did people lose on survodutide in the Lancet study?
Dr. Megan cites a 46-week Lancet study of over 300 people in which total body weight loss averaged 14.9%. She calls this extremely competitive compared with Wegovy, Ozempic, Mounjaro and Zepbound.
What side effects does Dr. Megan mention for survodutide?
She says about 91% of subjects on the drug had some sort of adverse event. She does not describe which events they were, and she says the larger phase three trials should show safety patterns more clearly.
Why is survodutide being discussed for fatty liver disease?
Dr. Megan says it seems to improve MASH, the newer name for fatty liver disease, and that measures of the condition have improved. She expects it would likely be approved for that use, which she says could broaden access to coverage.
Video by Weight Medicine with Dr. Meghan MD on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
